ACC: Esperion's Nexletol busts cholesterol levels regardless of statin, ezitimibe therapy

In multiple phase 3 trials, Esperion's Nexletol significantly lowered levels of high-sensitivity C-reactive protein in patients with abnormally high triglyceride levels whether they were actively taking standard-of-care statins or not, according to a pooled data analysis presented Saturday at the American College of Cardiology scientific sessions.